Skip to main content

Table 2 Results of base case analysis

From: Cost-effectiveness analysis of ceftazidime avibactam versus colistin in carbapenem-resistant enterobacteriaceae in Iran

Parameters

Col group

CA group

Increment

Cost

460

885

425

QALY

1.18

1.71

0.53

ICER

-

-

798

ACER

390

517

127

NMB

849

1015

166

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us